Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN7A | Q01118 | 7/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 15/20 | 0.52 |
| ▸ | SCN5A | Q14524 | 8/20 | 0.52 |
| ▸ | SCN1A | P35498 | 1/20 | 0.50 |
| ▸ | SCN4A | P35499 | 1/20 | 0.50 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.50 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.50 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16759180 | 0.89 | SCN7A (0.54) | SCN7ASCN9ASCN5ASCN1ASCN4A | |
| SCHEMBL16759382 | 0.88 | SCN5A (0.56) | SCN7ASCN9ASCN5ASCN1ASCN4A | |
| SCHEMBL16759539 | 0.84 | SCN9A (0.74) | SCN7ASCN9ASCN5ASCN1ASCN4A | |
| SCHEMBL16759209 | 0.76 | SCN7A (0.70) | SCN7ASCN9ASCN5ASCN1ASCN4A | |
| SCHEMBL16759128 | 0.75 | SCN7A (0.72) | SCN7ASCN9ASCN5ASCN1ASCN4A | |
| SCHEMBL16759745 | 0.73 | SCN9A (0.53) | SCN7ASCN9ASCN5A | |
| SCHEMBL30261423 | 0.73 | SCN9A (0.61) | SCN9ASCN5A | |
| SCHEMBL16759000 | 0.73 | SCN7A (0.75) | SCN7ASCN9ASCN5ASCN1ASCN4A | |
| SCHEMBL16759596 | 0.73 | SCN7A (0.55) | SCN7ASCN9ASCN5ASCN1ASCN4A | |
| SCHEMBL16759357 | 0.72 | SCN9A (0.72) | SCN7ASCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | SCN7A 1270/4885SCN9A 1605/4885SCN5A 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.